Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
This is a Phase II, non-randomized, open-label, single arm, continuation trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has completed 6 cycles of therapy in a prior Fujisawa-sponsored FK228 clinical trial;
Patient has immediate past participation (not to exceed 21 days from Day 15 of cycle 6 in the previous study) in a prior Fujisawa-sponsored FK228 clinical trial;
Patient has demonstrated stable disease, partial response or complete response as best overall response in their prior Fujisawa-sponsored FK228 clinical trial.
You may not be if
Patient has been on a prior Fujisawa-sponsored FK228 clinical trial, left the trial and then received alternative anti-neoplastic therapy
Clareo Health | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
